header photo: Science

Scientific Publications

 

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
K. Borroto-Esoda, S. Barat,  D. Angulo, C. Carruthers, K. Holden, P. Warn
IDWeek 2017
October 2017

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
S. Barat,  D. Angulo, K. Borroto-Esoda,  M. Ghannoum
IDWeek 2017
October 2017

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
S. Barat, K. Borroto-Esoda, D. Angulo, C. Carruthers
IDWeek 2017
October 2017

A Multicenter, Randomized, Evaluator-blinded, Active-controlled Study to Evaluate the Efficacy and Safety of Oral SCY-078 vs Oral Fluconazole in 96 Subjects with Moderate to Severe Vulvovaginal Candidiasis
S. Helou, D. Angulo
IDSOG 2017
August 2017

The Effect of pH on the In Vitro Antifungal Activity of SCY-078
E. Larkin, C. Hager, L. Long, N. Isham, S. Barat, K. Borroto-Esoda, S. Wring, D. Angulo, M. Ghannoum
IDSOG 2017
August 2017

Vaginal Concentrations of SCY-078, a Novel Glucan Synthase Inhibitor, Following Oral Administration in Mice
S. Barat, K. Borroto-Esoda, S. Wring, D. Angulo
IDSOG 2017
August 2017

SCY-078, a Novel Intravenous and Oral Antifungal Agent, Demonstrates Extensive Tissue Distribution in Rats Following Single Intravenous Infusions and Oral Doses of [14C]SCY-078 
S. Wring, E. Solon, D, Watson, S. Barat, D. Angulo
ASM Microbe 2017
June 2017

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Panel of Susceptible and Resistant, Clinical Candida Isolates from Europe
K. Borroto-Esoda, S. Birchall, C. B. Moore, D. Angulo
ASM Microbe 2017
June 2017

Susceptibility Testing of SCY-078 Against Candida Isolates Obtained from a Clinical Study of Oral SCY-078 vs. Oral Fluconazole in Subjects with Moderate to Severe Vulvovaginal Candidiasis Demonstrates no Resistance Development
K. Borroto-Esoda, D. Angulo, E. Larkin, I.Salem, L. Long, S. Helou, M. Ghannoum
ASM Microbe 2017
June 2017

A Lack of an Effect of SCY-078, a Novel Antifungal Agent on QTC Interval in Healthy Subjects
G. Murphy, B. Darpo, T. Marbury, M. Hyman, D. Angulo
ASM Microbe 2017
June 2017

Pharmacokinetics and Pharmacodynamics in Patients from a Phase 2, Multicenter, Open-Label, Randomized, Comparative Study of Oral SCY-078 vs. Standard-of-Care Following Initial Intravenous Echinocandin Therapy in the Treatment of Invasive Candidiasis (including Candidemia) in Hospitalized Non-neutropenic Adults
D. Angulo, S. Helou, S. Wring, S. Barat
ASM Microbe 2017
June 2017

Pharmacokinetics of SCY-078 following Intravenous Administration in Rabbits: Implications for Treatment of Experimental Invasive Pulmonary Aspergillosis
V. Petraitis, R. Petraitiene, B.W. Maung, F, Khan, K. Borroto-Esoda, D. Angulo, S. Barat, T. J. Walsh
ASM Microbe 2017
June 2017

In vitro Interaction between SCY-078, Echinocandins and Azoles against Susceptible & Resistant Candida spp. Determined by the Checkerboard Method
K. Borroto-Esoda, B. Scorneaux, D. Angulo, S. Helou
ASM Microbe
June 2017

CYP-mediated Drug Interaction Profile of SCY-078, a novel Glucan Synthase Inhibitor (GSI)
G. Murphy, M. Hyman, M. Willett, D. Angulo
ASM Microbe 2017
June 2017

A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vs standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis (including candidaemia) in hospitalized non-neutropenic adults (mycoses study group 010)
P. Pappas, J. Pullman, G. Thompson, W. Powderly, A. Spec, E. Tobin, J. Vazquez, S. Wring, D. Angulo, S. Helou, and the Investigators of the Mycoses Study Group
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

The emerging Candida auris: antifungal activity of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation
E. Larkin, C. Hager, J. Chandra, P. Mukherjee, M. Retuerto, I. Salem, L. Long, N. Isham, L. Kovanda, K. Borroto-Esoda, S. Wring, D. Angulo, M. Ghannoum
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

Evaluation of the antifungal activity of SCY-078 in combination with other antifungals against Aspergillus strains
L. Long, E. Larkin, K. Borroto-Esoda, S. Wring, D. Angulo, M. Ghannoum
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

Effect of SCY-078 on the pharmacokinetics of CYP2C8 substrate (rosiglitazone), results from a phase 1 clinical trial
D. Angulo, G. Atiee, C. Corr, M. Willett, G. Murphy, S. Wring
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

The effect of SCY-078 on the pharmacokinetics of tacrolimus, the results of a phase 1 drug-drug Interaction clinical trial
D. Angulo, G. Atiee, C. Corr, M. Willett, G. Murphy, S. Wring
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

A multicentre, randomized, evaluator-blinded, active-controlled study to evaluate the safety and efficacy of oral SCY-078 in subjects with moderate to severe vulvovaginal candidiasis
M. Roman, C. Hernandez, D. Blanco, G Obrycki, S. Helou, D. Angulo
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

Activity of SCY-078 against Candida spp. obtained by EUCAST and CLSI procedures
J. Guinea, L. Marcos-Zambrano, P. Escribano, E. Bouza Santiago
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

The novel oral glucan synthase inhibitor SCY-078 shows in-vitro activity against Candida spp. biofilms
J. Guinea, L. Marcos-Zambrano, M. Gomez-Perosanz, P. Escribano, E. Bouza Santiago
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

SCY-078; The First Orally Bioavailable, Glucan Synthase Inhibitor, Demonstrates Potent In-Vitro 
K. Borroto-Esoda, D. Angulo, S. Moser, J. Whiddon, P. Pappas, D. Perlin, S. Wring
13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis                                                                      April 2016

SCY-078 Displays Potent In-Vitro Activity Against Candida glabrata Isolates with Mutations in fks Gene 
K. Borroto-Esoda, D. Angulo, M. Castanheira, M. Pfaller, S. Wring 
13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis                                                                      April 2016

SCY-078 Displays Significance In-Vitro Activity Against Multi Drug Resistant (MDR) Candida albicans and Candida glabrata Isolates
K. Borroto-Esoda, D. Angulo, S. Moser, J. Whiddon, P. Pappas, S. Wring
13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis                                                                      April 2016

 

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species
Schell WA, Jones  AM, Borroto-Esoda K, Alexander B 
Antimicrobial Agents and Chemotherapy
November 2017

De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations that both Overlap and are Distinct from those Conferring Echinocandin Resistance
Jimenez-Ortigosa C, Perez WB, Angulo D, Borroto-Esoda K, Perlin DS 
Antimicrobial Agents and Chemotherapy
September 2017

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-resistant Strains of Candida Species
Pfaller MA, Messer SA, Rhomberg PR, Borroto-Esoda K, Castanheira M 
Antimicrobial Agents and Chemotherapy
August 2017

In vitro Activity of Novel Glucan Synthase Inhibitor SCY-078 against Clinical Isolates of Candida auris 
Berkow EL, Angulo D, Lockhart SR 
Antimicrobial Agents and Chemotherapy
July 2017

The Novel Oral Glucan Synthase Inhibitor SCY-078 shows In vitro Activity against Sessile and Planktonic Candida spp. 
Marcos-Zambrano LJ, Gomez-Perosanz M, Escribano P, Bouza E, Guinea 
Journal of Antimicrobial Chemotherapy
July 2017

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. 
S. Wring, R. Randolph, S. Park, G. Abruzzo, Q. Chen, A. Flattery, G. Garrett, M. Peel, R. Outcalt, K. Powell, M. Trucksis, D. Angulo, K. Borroto-Esoda
Antimicrobial Agents and Chemotherapy
March 2017

The Emerging Candida auris: Characterization of Growth Phenotype, Virulence Factors, Antifungal Activity, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. 
E. Larkin, C. Hager, J. Chandra, P. Mukherjee, M. Retuerto, I. Salem, L. Long, N. Isham, L. Kovanda, K. Borroto-Esoda, S. Wring, D. Angulo, M. Ghannoum
Antimicrobial Agents and Chemotherapy
February 2017

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. 
B. Scorneaux, D. Angulo, K. Borroto-Esoda, M. Ghannoum, M. Peel, S. Wring
Antimicrobial Agents and Chemotherapy
February 2017